Vinflunine: a novel antitubulin agent in solid malignancies (Q36268368)

13 August 2017

1 reference

title

Vinflunine: a novel antitubulin agent in solid malignancies (English)

1 reference

13 August 2017

Jaafar Bennouna

1

1 reference

13 August 2017

Mario Campone

series ordinal

2

1 reference

13 August 2017

Jean Pierre Delord

series ordinal

3

1 reference

13 August 2017

Marie-Claire Pinel

series ordinal

4

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

Expert Opinion on Investigational Drugs

13 August 2017

published in

1 reference

13 August 2017

volume

14

1 reference

13 August 2017

issue

10

1 reference

13 August 2017

page(s)

1259-1267

1 reference

Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.10.1259

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.10.1259

In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.10.1259

Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.10.1259

Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.10.1259

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.10.1259

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.10.1259

10.1517/13543784.14.10.1259

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference